Psoriatic arthritis can cause enthesosynovial inflammation and structural damage, which translates into a substantial decrease in functional capacity and an impact on quality of life.1 Treatment ...options for psoriatic arthritis are varied; however, a substantial number of patients do not reach their treatment goals. ...the search for new approaches to treating the disease and for new therapeutic molecules continues to be essential.2 Interleukin (IL)-17A has emerged as a pivotal molecule in driving tissue inflammation in several immune-mediated inflammatory diseases, and biological therapies targeting this cytokine have been effective in treating psoriatic arthritis.2 However, the role of IL-17F, which shares 50% sequence homology and overlapping biological function with IL-17A, remains less clear. ...it is expected that direct comparison studies between bimekizumab and other treatment options for psoriatic arthritis will overcome the limitations of the current placebo-compared trials. ...the efficacy of bimekizumab in terms of ACR50 response was practically the same in BE OPTIMAL and BE COMPLETE.5,6 Finally, more studies will be necessary to answer questions and doubts that the BE OPTIMAL and BE COMPLETE trials have not been able to answer.10 In any case, bimekizumab is a new effective and safe option for the treatment of psoriatic arthritis.
PDF
